Copy
See below for a daily digest of the latest Huntington's Disease news!

Blocking Certain Glutamate Receptors Seen to Ease Huntington’s Advance in Mouse Model of Disease

Mar 05, 2018 07:00 am | Jose Marques Lopes, PhD

 

mouse model of disease studyBlocking specific glutamate receptors was seen to improve cellular, motor, and cognitive skills in a mouse model of Huntington’s disease. The study, “mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington’s disease,” appeared in the journal Science Signaling. Glutamate is the main excitatory neurotransmitter in the brain. Metabotropic glutamate receptor 5 […]

The post Blocking Certain Glutamate Receptors Seen to Ease Huntington’s Advance in Mouse Model of Disease appeared first on Huntington's Disease News.

Read More
share on Twitter Like Blocking Certain Glutamate Receptors Seen to Ease Huntington’s Advance in Mouse Model of Disease on Facebook

Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National

Mar 01, 2018 11:50 am | Larry Luxner

 

Retrophin and the U.S. subsidiary of Britain’s Horizon Pharma will each donate $3 million over a six-year period to the Rare Disease Institute (RDI) at Children’s National Health System in Washington, D.C., helping it to strengthen care available and expand as a “center of excellence” for rare disease patients. “We’re really proud of both these companies […]

The post Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National appeared first on Huntington's Disease News.

Read More
share on Twitter Like Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National on Facebook

Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status

Mar 01, 2018 07:00 am | Carolina Henriques

 

EHP-102, orphan drug statusThe U.S. Food and Drug Administration recently granted orphan drug status to Emerald Health’s EHP-102, an investigative therapy for Huntington’s disease. EHP-102 is a patented cannabigerol (CBG) derivative in development for the treatment of Huntington’s and Parkinson’s disease. CBG is a natural cannabinoid with potent effects that has been shown to have anti-inflammatory properties and evidence of neuroprotective […]

The post Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status appeared first on Huntington's Disease News.

Read More
share on Twitter Like Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status on Facebook

Huntington’s Patients’ Skin Cells Transformed Into Nerve Cells That Mimic Disease Symptoms

Feb 27, 2018 09:30 am | Alice Melão

 

skin cells of Huntington'sNerve cells that mimic the molecular features of Huntington’s disease have been created from patients’ skin cells, researchers said. The study, “Striatal neurons directly converted from Huntington’s disease patient fibroblasts recapitulate age-associated disease phenotypes,” was published in Nature Neuroscience. These engineered nerve cells exhibit many of the cellular “symptoms” that characterize the disease, like increased DNA […]

The post Huntington’s Patients’ Skin Cells Transformed Into Nerve Cells That Mimic Disease Symptoms appeared first on Huntington's Disease News.

Read More
share on Twitter Like Huntington’s Patients’ Skin Cells Transformed Into Nerve Cells That Mimic Disease Symptoms on Facebook

BioNews to Cover 3 Rare Disease Day Events, Including NIH Conference

Feb 27, 2018 07:00 am | Larry Luxner

 

NY Genome CenterIn recognition of Rare Disease Day 2018, BioNews Services — which publishes this website — will attend and report on three relevant conferences in the U.S. dealing with policies and programs of importance to patients and their families. The three are among 50 events in 32 states and the District of Columbia planned by patient […]

The post BioNews to Cover 3 Rare Disease Day Events, Including NIH Conference appeared first on Huntington's Disease News.

Read More
share on Twitter Like BioNews to Cover 3 Rare Disease Day Events, Including NIH Conference on Facebook

Recent Posts

Huntington’s Disease May Start Very Early in Embryo, Research Reveals
Patient Advocacy Groups Worldwide Plan Events to Mark Rare Disease Day, Feb. 28
Rare Disease Groups, Patients Differ on ‘Right to Try’ Bill Before US Congress
Link Between Exact Mutation and Huntington’s Progression May Aid in Early Prognosis, Report Suggests
Vaccinex Holding Business Opinion Leaders Luncheon on Huntington’s in New York City

Copyright © 2018 BioNews Services, LLC, All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences